https://www.selleckchem.com/pr....oducts/nocodazole.ht
Interferon beta (IFN ) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades. However, there is still a lack of treatment response markers that correlate with the clinical outcome of patients. To determine a combination of cellular and molecular blood signatures associated with the efficacy of IFN treatment using an integrated approach. The immune status of 40 RRMS patients, 15 of whom were untreated and 25 that received IFN 1a treatment (15 responders
Curtir
Comentario
Compartilhar
